{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:55:15Z","timestamp":1787882115732,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kowa Company, Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.conctc.2019.100516","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T18:10:53Z","timestamp":1577815853000},"page":"100516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)"],"prefix":"10.1016","volume":"17","author":[{"given":"Anna","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-1386","authenticated-orcid":false,"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-4851","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Kurihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2019.100516_bib1","series-title":"Evidence-based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis","year":"2014"},{"issue":"1","key":"10.1016\/j.conctc.2019.100516_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.conctc.2019.100516_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/gast.2001.27126","article-title":"Nonalcoholic steatohepatitis","volume":"121","author":"Reid","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.conctc.2019.100516_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.conctc.2019.100516_bib5","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.conctc.2019.100516_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"42","key":"10.1016\/j.conctc.2019.100516_bib7","doi-asserted-by":"crossref","first-page":"e4947","DOI":"10.1097\/MD.0000000000004947","article-title":"Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials","volume":"95","author":"He","year":"2016","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.conctc.2019.100516_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.conctc.2019.100516_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.conctc.2019.100516_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.conctc.2019.100516_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"10","key":"10.1016\/j.conctc.2019.100516_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.conctc.2019.100516_bib13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1507\/endocrj.EJ17-0206","article-title":"Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U\/mL using continuous glucose monitoring (CGM): a randomized crossover study","volume":"64","author":"Takeishi","year":"2017","journal-title":"Endocr. J."},{"issue":"7","key":"10.1016\/j.conctc.2019.100516_bib14","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/nutd.2014.20","article-title":"Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models","volume":"4","author":"Suzuki","year":"2014","journal-title":"Nutr. Diabetes"},{"issue":"5","key":"10.1016\/j.conctc.2019.100516_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.conctc.2019.100516_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejrad.2017.11.003","article-title":"MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease","volume":"98","author":"Costa-Silva","year":"2018","journal-title":"Eur. J. Radiol."},{"issue":"6","key":"10.1016\/j.conctc.2019.100516_bib17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/jmri.21751","article-title":"Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling","volume":"29","author":"Reeder","year":"2009","journal-title":"J. Magn. Reson. Imaging"},{"issue":"3","key":"10.1016\/j.conctc.2019.100516_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865419302790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865419302790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:03:24Z","timestamp":1762520604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865419302790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"alternative-id":["S2451865419302790"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2019.100516","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2019.100516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100516"}}